News coverage about RadNet (NASDAQ:RDNT) has trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RadNet earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.9614033223814 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- RadNet Inc. (RDNT) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- RadNet (RDNT) Announces Earnings Results, Misses Expectations By $0.02 EPS (americanbankingnews.com)
- RadNet Reports Second Quarter Financial Results to Include Record Revenue and Reaffirms Guidance Ranges (globenewswire.com)
- RadNet, Inc. (RDNT) CEO Howard Berger on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- RadNet (RDNT) Q2 Earnings and Revenues Beat Estimates (zacks.com)
Shares of RDNT stock traded up $0.25 during trading hours on Friday, hitting $14.05. The company’s stock had a trading volume of 150,105 shares, compared to its average volume of 144,428. The company has a market capitalization of $665.71 million, a P/E ratio of 40.59, a price-to-earnings-growth ratio of 4.73 and a beta of 0.32. The company has a debt-to-equity ratio of 4.90, a current ratio of 1.12 and a quick ratio of 1.12. RadNet has a 12-month low of $7.80 and a 12-month high of $15.50.
RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Thursday, August 9th. The medical research company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). RadNet had a positive return on equity of 18.87% and a negative net margin of 0.64%. The firm had revenue of $244.40 million for the quarter, compared to analysts’ expectations of $239.34 million. During the same period last year, the company posted $0.11 earnings per share. The business’s quarterly revenue was up 6.3% on a year-over-year basis. sell-side analysts forecast that RadNet will post 0.37 earnings per share for the current year.
Several research firms recently commented on RDNT. BidaskClub lowered shares of RadNet from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 11th. ValuEngine upgraded shares of RadNet from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of RadNet from a “sell” rating to a “hold” rating in a research note on Wednesday, May 16th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $14.75.
In other news, insider Norman R. Hames sold 10,000 shares of the stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $12.81, for a total value of $128,100.00. Following the completion of the sale, the insider now directly owns 312,450 shares in the company, valued at $4,002,484.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Norman R. Hames sold 15,000 shares of the stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $12.77, for a total transaction of $191,550.00. Following the completion of the sale, the insider now owns 322,450 shares of the company’s stock, valued at $4,117,686.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,000 shares of company stock worth $922,750. Insiders own 7.56% of the company’s stock.
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.